Contribute Try STAT+ Today

CVS Health recently expanded its investing efforts with the launch of the CVS Venture Fund, a $100 million vehicle to provide promising upstarts with access to CVS’ wealth of financial and strategic expertise and generous physical footprint.

While the retail and pharmacy giant had previously backed more than 20 upstarts through a partnership between CVS Pharmacy and Aetna Ventures, it was spurred to create the new fund after seeing how the pandemic changed in health care delivery, including the rise of digital pharmacies and increasing interest in at-home testing and treatment, Josh Flum, CVS’ executive vice president of enterprise strategy and digital, told STAT.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.